

Special Issue

Molecular Biomarkers of Solid Tumors

Message from the Guest Editor

Cancer remains the leading cause of death worldwide. Successful cancer treatment is largely determined by early detection, risk assessment, efficient therapies, and treatment monitoring. These processes can be associated with one or more specific molecular markers, which can be genetic mutations, epigenetic changes, mRNA and/or protein expression levels, and metabolite levels. Molecular markers can be quantified in biological samples, including tumor tissue biopsy, blood, plasma, etc. Over the past ten years, the development of new technologies, e.g., routine utilization of Next-Generation Sequencing techniques in molecular diagnostic laboratories, has greatly facilitated the identification and detection of molecular markers, and significantly improved the clinical utilities of these molecular markers in cancer risk assessment, diagnosis (primary or metastatic), disease subclassification, prognosis, personalized therapy, treatment prediction and monitoring. This Special Issue will focus on the identification and detection of molecular markers and their clinical utilities in solid tumors.

Guest Editor

Dr. Hanxin Lin

Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada

Deadline for manuscript submissions

closed (25 October 2022)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/106227

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2
(Genetics (clinical))